Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia

Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab

(2016) Tomonori Tadokoro et al.   Circulation-Heart Failure

Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy

(2016) Christian Besler et al.   EUROPEAN JOURNAL OF HEART FAILURE

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

(2016) Jose Luis Zamorano et al.   EUROPEAN JOURNAL OF HEART FAILURE

Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma

(2016) Anurag Mehta et al.   MELANOMA RESEARCH

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

(2016) Matthew S. Davids et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

(2015) Heinz Läubli et al.   Journal for ImmunoTherapy of Cancer

Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome

(2015) Benjamin P Geisler et al.   Journal for ImmunoTherapy of Cancer